This is an email that I sent to the Company today. As you are...

This is an email that I sent to the Company today.

As you are well aware, I am a shareholder of Chimeric Therapeutics (ASX: CHM) and have been in active correspondence with the company on several matters, including the current dispute regarding access to the share register.

I now write in relation to the investor webinar held on Thursday, 22nd May 2025, during which CEO Rebecca McQualter stated that the ASX had advised the company that the results of its “first-in-the-world” clinical trial for CHM CDH-17 were not market sensitive and could therefore be released via social media.

I submitted a question during that webinar specifically requesting clarification on this claim and a copy of the ASX’s advice, but my question was not put to the CEO and remains unanswered.

Accordingly, I formally request that Chimeric Therapeutics now provide me with a copy of the advice or correspondence from the ASX that supports Ms. McQualter’s assertion. If the company is unwilling or unable to provide the actual correspondence, I expect a detailed summary of the advice including:

• The date it was received;

• The ASX officer or team it was received from; and

• The rationale provided for determining the trial results were not market sensitive.

In addition, I would appreciate the company’s explanation as to why — even if the ASX had indicated the information was not market sensitive — the company did not release the trial results via the ASX platform as a “non-market-sensitive” announcement. As you would be aware, ASX Listing Rule 3.1 and ASX Guidance Note 8 – Continuous Disclosure expressly allow companies to release information on the ASX platform that is not considered market sensitive, and ASX actively encourages this as part of good disclosure practice.

Guidance Note 8 also clearly warns that social media and other informal communication channels are not appropriate substitutes for announcements via the ASX platform, even in the case of non-sensitive information. The decision to release clinical trial data — which ASX identifies as potentially market sensitive — only through social media raises serious concerns about transparency and equitable access to information.

I also note that during the webinar, CEO Rebecca McQualter emphasised that corporate governance is "really important" to her, and described the co-company secretary, Nathan, as a “wizard” at corporate governance. However, it was Nathan who previously advised me that my application for access to the share register was “invalid”, and has since refused to provide any explanation as to why. This inconsistency between the company’s stated commitment to governance and its actual practices only heightens my concern.

Please note that, in the interest of transparency, I will be sharing this correspondence with fellow shareholders across relevant investor forums and social media platforms.

Regards,